Scientists have gotten the first close look at one of two co-receptors HIV uses to get its foot in the door of the immune system, a new study reports. Their insights could lead to better HIV drugs.

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with ...

Human immunodeficiency virus (HIV) infection is a viral infection that causes acquired immunodeficiency syndrome (AIDS) by gradually destroying certain leukocytes. When HIV enters the human body, it ...

In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, SevenScore will receive 4,094,023 shares of Regnum Corp. In the setting of HIV/AIDS, ...

For the seventh time on record, a patient with both HIV and cancer has had the virus eliminated from their body. As in most ...

A seventh patient has achieved sustained HIV remission after allogeneic hematopoietic stem cell transplantation, according to a new case report. The patient, known as the "next Berlin patient," has ...

Details of a 60-year-old male individual from Germany who achieved sustained HIV remission after a stem cell transplant, the ...

VANCOUVER, Washington, March 29, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a ...

Co-receptor tropism has been identified to correlate with HIV-1 transmission and the disease progression in patients. A molecular epidemiology investigation of co-receptor tropism is important for ...

Company to deliver oral and poster presentations for data on leronlimab’s action on PD-L1 expression and patient survival in triple-negative breast cancer VANCOUVER, Washington, Sept. 25, 2025 (GLOBE ...